|
|
||||||||
1Department of Cell Biology and Neurosciences, Istituto Superiore di Sanità, Rome; and 2Department of Clinical Sciences, "La Sapienza" University, Rome, Italy
Submitted 7 December 2004 ; accepted in final form 22 April 2005
Aging is characterized by renal functional and structural abnormalities resembling those observed in diabetes. These changes have been related to the progressive accumulation of advanced glycation end-products (AGEs) and cumulative oxidative stress occurring in both conditions. We previously reported that galectin-3 ablation is associated with increased susceptibility to diabetes- and AGE-induced glomerulopathy, thus indicating a protective role of galectin-3 as an AGE receptor. To investigate the role of the AGE/AGE receptor pathway in the pathogenesis of age-related renal disease, we evaluated the development of glomerular lesions in aging galectin-3 knockout (KO) vs. wild-type (WT) mice and their relation to the increased AGE levels and oxidative stress characterizing the aging process. KO mice showed significantly more pronounced age-dependent increases in proteinuria, albuminuria, glomerular sclerosis, and glomerular and mesangial areas, starting at 18 mo, as well as renal extracellular matrix mRNA and protein expression, starting at 12 mo vs. age-matched WT mice. Circulating and renal AGEs, plasma isoprostane 8-epi-PGF2
levels, glomerular content of the glycoxidation and lipoxidation products N
-carboxymethyllysine and 4-hydroxy-2-nonenal, and renal nuclear factor-
B activity also increased more markedly with age in KO than WT mice. AGE levels correlated significantly with renal functional and structural parameters. These data indicate that aging galectin-3 KO mice develop more pronounced changes in renal function and structure than coeval WT mice, in parallel with a more marked degree of AGE accumulation, oxidative stress, and associated low-grade inflammation, thus supporting the concept that the AGE/AGE receptor pathway is implicated in age-related renal disease.
age-related glomerulopathy; advanced glycation end-products; advanced glycation end-product receptors; oxidative stress
This article has been cited by other articles:
![]() |
D. Delacour, A. Koch, W. Ackermann, I. E.-L. Parco, H.-P. Elsasser, F. Poirier, and R. Jacob Loss of galectin-3 impairs membrane polarisation of mouse enterocytes in vivo J. Cell Sci., February 15, 2008; 121(4): 458 - 465. [Abstract] [Full Text] [PDF] |
||||
![]() |
M Butscheid, P Hauptvogel, P Fritz, U Klotz, and D M Alscher Hepatic expression of galectin-3 and receptor for advanced glycation end products in patients with liver disease J. Clin. Pathol., April 1, 2007; 60(4): 415 - 418. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Menini, L. Amadio, G. Oddi, C. Ricci, C. Pesce, F. Pugliese, M. Giorgio, E. Migliaccio, P. Pelicci, C. Iacobini, et al. Deletion of p66Shc Longevity Gene Protects Against Experimental Diabetic Glomerulopathy by Preventing Diabetes-Induced Oxidative Stress Diabetes, June 1, 2006; 55(6): 1642 - 1650. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |